BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared

SG&A Spending Patterns: BioMarin vs. Viking Therapeutics

In the competitive landscape of biotechnology, understanding spending patterns is crucial. BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc. offer a fascinating case study in strategic financial management. Over the past decade, BioMarin has consistently increased its Selling, General, and Administrative (SG&A) expenses, growing by approximately 210% from 2014 to 2023. This reflects their aggressive expansion and investment in market presence. In contrast, Viking Therapeutics, while starting from a much smaller base, has seen a staggering increase of nearly 2,900% in the same period, indicating rapid growth and scaling efforts.

BioMarin's SG&A expenses peaked in 2023, reaching nearly 940 million, while Viking's expenses, though significantly lower, surged to 37 million. This divergence highlights differing growth strategies: BioMarin's steady expansion versus Viking's explosive growth. As these companies continue to evolve, their SG&A spending will remain a key indicator of their strategic priorities and market positioning.